================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 AMENDMENT NO. 1
                                       TO
                                  FORM 10-KSB/A

                 [X] ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                   For the fiscal year ended December 31, 2003

                        COMMISSION FILE NUMBER 001-14257


                                  XTRANA, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

           DELAWARE                                              58-1729436
(State or Other Jurisdiction of                               (I.R.S. Employer
 Incorporation or Organization)                              Identification No.)

    P.O. BOX 668, SEDALIA, COLORADO                                80135
(Address of Principal Executive Offices)                         (Zip Code)

       Registrant's telephone number (including area code) (303) 466-4424

        Securities registered pursuant to section 12(b) of the Act: None

           Securities registered pursuant to section 12(g) of the Act:

                               TITLE OF EACH CLASS

                     Common Stock, par value $.01 per share
                          Common Stock Purchase Rights

--------------------------------------------------------------------------------

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. [X] Yes [_] No

Check if there is no disclosure of delinquent  filers in response to Item 405 of
Regulation  S-B is not  contained  in  this  form,  and no  disclosure  will  be
contained,  to the  best of  registrant's  knowledge,  in  definitive  proxy  or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [X]

State Issuer's revenues for its most recent fiscal year: $1,191,000.

The aggregate market value of Xtrana, Inc. Common Stock, $.01 par value, held by
non  affiliates,  computed  by  reference  to the average of the closing bid and
asked prices as reported by OTCBB on December 31, 2003, was $1,938,992.

Number of shares of Common  Stock of Xtrana,  Inc.,  $.01 par value,  issued and
outstanding as of February 8, 2004: 16,533,269.

Transitional Small Business Disclosure Format (Check one): Yes [_]; No [X]

================================================================================


<PAGE>


                                 AMENDMENT NO. 1
                  TO THE ANNUAL REPORT ON FORM 10-KSB FILED BY
                         XTRANA, INC. ON MARCH 19, 2004

         The  following  Items amend the Annual  Report on Form 10-KSB  filed by
Xtrana, Inc. (the "Company") on March 19, 2004 (the "Form 10-KSB"), as permitted
by the  rules  and  regulations  promulgated  by  the  Securities  and  Exchange
Commission. The Form 10-KSB is hereby amended to insert those Items as set forth
herein.  All  capitalized  terms  used  herein  but not  defined  shall have the
meanings ascribed to them in the Form 10-KSB.


                                    PART III

ITEM 9.  DIRECTORS AND EXECUTIVE OFFICERS;  COMPLIANCE WITH SECTION 16(A) OF THE
         EXCHANGE ACT

INFORMATION WITH RESPECT TO EACH DIRECTOR, NOMINEE AND CERTAIN OFFICERS.

         The following table sets forth certain information with respect to each
director, nominee and executive officer of the Company as of April 23, 2004.

<TABLE>
<CAPTION>
                                                                              DIRECTOR/
                                                                               OFFICER
        NAME              AGE                        POSITION                   SINCE
----------------------    ---    -----------------------------------------    ---------
<S>                       <C>    <C>                                             <C>
Michael D. Bick, Ph.D.    59     Chairman of the Board, Director                 1991
James H. Chamberlain      56     Interim Chief Executive Officer and Chief
                                   Financial Officer and Director                1998
John C. Gerdes, Ph.D.     55     Chief Scientific Officer and Director           2000
Douglas L. Ayer           66     Director                                        1993
N. Price Paschall         55     Director                                        1997
James B. Mahony           54     Director                                        2002
</TABLE>

         All officers are appointed by and serve at the  discretion of the Board
of  Directors.  There are no  family  relationships  between  any  directors  or
officers of the Company.

         MICHAEL D. BICK,  PH.D. was elected Chief  Executive  Officer in August
1991,  Chairman  of the  Board  in July  1993 and  President  in  January  1996.
Subsequent to the Company's merger with Biopool International,  Inc. ("Biopool")
in August 2000 (the "Merger"),  Dr. Bick retired as Chief Executive  Officer and
President. In 1988, Dr. Bick founded the Company's former subsidiary,  MeDiTech,
and was President and Chief  Executive  Officer thereof until it was acquired by
Biopool in January 1992.  Prior to that date, he was co-founder and president of
a privately held medical device firm for ten years. Dr. Bick received a Ph.D. in
molecular  biology from the  University  of Southern  California in 1971 and was
affiliated  with the Harvard  Medical  School and  Children's  Hospital  Medical
Center in Boston  carrying out research in human genetics from 1971 to 1974. Dr.
Bick was a staff member of the Roche Institute of Molecular Biology from 1974 to
1978.  Dr. Bick  currently  serves on the Board of  Counselors  of the School of
Pharmacy,  University of Southern  California.  Dr. Bick is also on the Board of
Directors of  Biotech.com,  a privately  held company  that  supplies  goods and
services to the biotech/biopharma industry.

         JAMES H. CHAMBERLAIN was appointed  Interim Chief Executive Officer and
Chief  Financial  Officer of the  Company in March  2004,  and has served on the
Board of  Directors  since 1998.  Mr.  Chamberlain  was the founder of BioSource
International,  Inc., a California-based,  Nasdaq National Market System company
dedicated  to  the  research,  development,   manufacturing,  and  marketing  of
biomedical products to the diagnostic and research markets.


                                       2
<PAGE>


Mr.  Chamberlain  founded  BioSource  in 1989,  and  retired  as a  director  of
BioSource and as its Chairman,  President,  and Chief Executive Officer in 2000.
Prior to BioSource,  Mr. Chamberlain was the Manager of Business Development for
Amgen,  Inc.  Mr.  Chamberlain  also serves on the Board of Directors of EcoSoil
Systems,  Inc., an agricultural  biotechnology firm. Mr. Chamberlain  received a
B.S.  degree in biology and chemistry from West Virginia  University in 1969 and
completed an MBA Executive Program at Pepperdine University in 1981.

         JOHN C.  GERDES,  PH.D.  became a  director  and the  Chief  Scientific
Officer  concurrent with the Company's merger with Biopool in 2000. In 2003, Dr.
Gerdes  resigned  as a director of the  Company  due, in part,  to his desire to
submit an offer for the purchase of the  Company's  intellectual  property.  Dr.
Gerdes was  reappointed  to the  Company's  Board of Directors in March 2004. In
1996, he conceived of a unique point of care approach for DNA  diagnostics,  the
development of which resulted in the formation of Xtrana.  From 1988 to 1998, he
was the  Director of Paternity  Analysis  and Clinical  Director at IAD where he
supervised  clinical  testing and  introduced  PCR and other  nucleic acid based
clinical tests. He has twenty-one  publications  primarily  focused on molecular
methods of virus detection.  He has recently filed four patents that provide the
technical  foundation of the Xtrana business plan. Dr. Gerdes received a B.S. in
Microbiology  from the  University of Wyoming in 1970,  and a Ph.D. in Microbial
Genetics from the University of California at Los Angeles (UCLA) in 1974.  After
completing a four-year post-doctoral  fellowship in Virology,  again at UCLA, he
spent four years as an assistant  professor at the University of Colorado Health
Sciences  Center  in  Denver  before   accepting  a  position  at  Immunological
Associates of Denver (IAD), a specialty reference testing laboratory.

         DOUGLAS L. AYER has served as a member of the Board of Directors  since
1993.  Mr. Ayer is currently  President  and Managing  Partner of  International
Capital  Partners of Stamford,  CT. Mr. Ayer was  previously  Chairman and Chief
Executive  Officer of Cametrics,  a manufacturer of precision metal  components,
and has held  executive  positions at Paine Webber and McKinsey & Co.,  Inc. Mr.
Ayer also serves as a director of a number of private companies,  largely in the
information technology sector.

         N.  PRICE  PASCHALL  has  served as a member of the Board of  Directors
since 1997. Mr. Paschall is the founder and Managing  Partner of Context Capital
Group (formerly  HealthCare  Capital Advisors) since 1993. Context Capital Group
provides merger and acquisition  advice to middle market companies,  focusing on
the medical service industry. Prior to Context Capital Group, Mr. Paschall was a
Vice Chairman and founder of Shea, Paschall and Powell-Hambros Bank (SPP Hambros
& Co.), a firm  specializing in mergers and  acquisitions.  Mr. Paschall holds a
degree in business  administration  from  California  Polytechnic  University in
Pomona.  Since  1994,  Mr.  Paschall  has served on the Board of  Directors  and
provided certain  corporate  financial  services to Advanced  Materials Group, a
manufacturer   and   fabricator   of   specialty   foams,   foils,   films   and
pressure-sensitive adhesive components.

         JAMES B. MAHONY PH.D.  has served as a member of the Board of Directors
since  2002.  Dr.  Mahony  began his career  with the  University  of  Toronto's
Department of Microbiology  and  Parasitology,  and has held numerous  positions
with McMaster University,  including serving as the Director of the University's
Regional Virology and  Chlamydiology  Laboratory at St. Joseph's  Hospital.  Dr.
Mahony has authored 140  publications,  many of which deal with either chlamydia
or gonorrhea.  He has also  published 49 articles in books,  several  discussing
sexually transmitted diseases and chlamydia.  His laboratory frequently conducts
and  publishes  validation  studies of new  methods  for  detection  of sexually
transmitted  disease  infectious  agents. Dr. Mahony is currently a Professor in
the  Department of Pathology and  Molecular  Medicine at McMaster  University in
Hamilton, Ontario, Canada, and also serves as a member of the Professional Staff
of Hamilton Health Sciences Corporation,  Laboratory Medicine. In addition,  Dr.
Mahony is President Elect of the Pan American Society of Clinical Virology.

AUDIT COMMITTEE FINANCIAL EXPERT

         The Audit Committee  currently consists of Messrs.  Ayer,  Paschall and
Bick. The Board of Directors has determined  that Mr. Ayer is an audit committee
financial  expert,  as defined  in Item  401(e)(2)  of  Regulation  S-B,  and is
"independent" within the meaning of Item 401(e)(1)(ii) of Regulation S-B.


                                       3
<PAGE>


SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

         Section  16(a) of the  Securities  Exchange  Act of 1934,  requires our
executive  officers,  directors,  and persons who own more than ten percent of a
registered  class of our equity  securities  to file  reports of  ownership  and
changes in ownership  with the  Securities  and Exchange  Commission.  Executive
officers,  directors and  greater-than-ten  percent stockholders are required by
Securities  and Exchange  Commission  regulations to furnish us with all Section
16(a)  forms  they file.  Based  solely on our review of the copies of the forms
received by us and written  representations  from certain reporting persons that
they have  complied  with the relevant  filing  requirements,  we believe  that,
during the year ended December 31, 2003, all our executive  officers,  directors
and greater-than-ten percent stockholders complied with all Section 16(a) filing
requirements.

CODE OF ETHICS DISCLOSURE

         The Company has adopted a Code of Ethical  Conduct  which is applicable
to all  of its  officers,  directors  and  employees,  including  its  principal
executive officer, principal financial officer, principal accounting officer and
persons performing  similar functions.  A copy of the Code of Ethical Conduct is
filed as an exhibit to this Amendment to Annual Report on Form 10-KSB.

ITEM 10. EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION

         The following tables set forth certain  information as to the Company's
Chairman,  Chief  Executive  Officer  and  Chief  Financial  Officer  and  Chief
Scientific Officer (the "Named Executive Officers").  No other executive officer
of the Company had compensation in excess of $100,000 during the period:

SUMMARY COMPENSATION TABLE

                                        ANNUAL COMPENSATION           SECURITIES
                                    -------------------------------   UNDERLYING
NAME AND PRINCIPAL POSITION  YEAR    SALARY     BONUS      OTHER(1)      OPTIONS
---------------------------  ----   -------    -------    ---------   ----------
Michael D. Bick, Ph.D.       2003    89,100        --      15,818             --
 Chairman of the Board       2002   140,400        --       9,600         55,000
                             2001   140,400        --       9,600             --

Timothy J. Dahltorp (2)      2003   200,000        --          --             --
 Chief Executive Officer     2002   200,000    20,000       4,042             --
                             2001   184,898    20,000          --        200,000

John C. Gerdes, Ph.D.        2003   145,600        --          --             --
 Chief Scientific Officer    2002   145,600        --          --             --
                             2001   144,093        --       2,882             --

----------
(1)      Represents  payment  of  a  car  allowance  and  contributions  to  the
         Company's 401(k) profit sharing plan. Dr. Bick's other compensation for
         2003 includes $6,000 for director fees.
(2)      Mr. Dahltorp resigned from the Company, effective as of March 19, 2004.


OPTION GRANTS IN LAST FISCAL YEAR

         No stock  options  grants  were  made to the Named  Executive  Officers
during the fiscal year ended December 31, 2003.


                                       4
<PAGE>


AGGREGATED  OPTION  EXERCISES  IN LAST  FISCAL YEAR AND FISCAL  YEAR-END  OPTION
VALUES

         The  following  table  sets  forth,  for  each of the  Named  Executive
Officers,  certain  information  regarding  the number of shares of common stock
underlying  stock options held at fiscal  year-end and the value of options held
at fiscal  year-end  based upon the last reported  sales price of the underlying
securities on the OTC Bulletin Board ($0.12 per share) on December 31, 2003, the
last trading day during 2003, as reported by the OTC Bulletin  Board. No options
were exercised by the Named Executive Officers during fiscal 2003.

<TABLE>
<CAPTION>
                                                                 VALUE OF UNEXERCISED
                            NUMBER OF UNEXERCISED OPTIONS             IN-THE-MONEY
                                    AT YEAR-END                  OPTIONS AT YEAR-END(1)
                            -----------------------------    ---------------------------
NAME                         EXERCISABLE / UNEXERCISABLE     EXERCISABLE / UNEXERCISABLE
-------------------------   -----------------------------    ---------------------------
<S>                               <C>                                  <C>
Michael D. Bick, Ph.D....           67,499 / 2,501                     $ 0 / 0
Timothy J. Dahltorp (2)..         340,411 / 159,589                      0 / 0
John C. Gerdes, Ph.D.....                0/0                             --/--

----------
<FN>
(1)      Determined  as the  difference  between  the  closing  trade  price  on
         December 31, 2003  ($0.12/share) and the aggregate price of the options
         covering such shares.
(2)      Mr.  Dahltorp  resigned from the Company  effective March 19, 2004. All
         unexercised  options  held  by Mr.  Dahltorp  will  terminate  90  days
         following the date of his resignation.
</FN>
</TABLE>


EMPLOYMENT AGREEMENTS WITH EXECUTIVE OFFICERS

         In March 2004,  we entered  into a consulting  agreement  with James H.
Chamberlain,  pursuant to which Mr.  Chamberlain  agreed to serve as our interim
Chief  Executive  Officer and interim Chief Financial  Officer.  The term of the
agreement  is  six  months  or,  if  earlier,  until  the  closing  of a  merger
transaction.  In exchange for these services,  we agreed to pay Mr.  Chamberlain
$30,000, payable in equal monthly installments during the term of the agreement.

         In February  2002,  the Company  entered into an  executive  employment
agreement with John C. Gerdes, Ph.D. Under the agreement,  Dr. Gerdes will serve
as  Chief  Scientific  Officer  of the  Company  for a period  of 3  years.  The
agreement provides for a base salary of $145,600 per year, plus annual incentive
compensation  as  determined  by the  Compensation  Committee  of the  Board  of
Directors.  The  agreement  also  provides  for  severance of up to 90 days base
salary if the agreement is terminated by the Company under certain conditions.

         In August 2001, we entered into an executive  employment agreement with
Timothy J. Dahltorp. Pursuant to this agreement, Mr. Dahltorp agreed to serve as
our Chief Executive Officer and Chief Financial Officer for a period of 3 years.
The  agreement  provided  for a base  salary of $200,000  per year,  plus annual
incentive  compensation as determined by the Compensation Committee of the Board
of Directors. The agreement also provided for severance of up to one year's base
salary if the agreement is  terminated  by us without  cause or by Mr.  Dahltorp
upon a change in control.  Pursuant to the  employment  agreement,  our entering
into the  Assignment  Agreement  with Applera  constituted a "change of control"
and, in accordance with the terms of the Agreement,  Mr. Dahltorp terminated the
employment  agreement  effective as of March 19, 2004.  As a result,  we will be
obligated  to continue  to pay Mr.  Dahltorp  his base salary of $200,000  for a
period of 12 months following such termination.

COMPENSATION OF DIRECTORS

         Non-employee  directors  receive $6,000 per calendar year,  plus $1,250
for  each in  person  Board  of  Directors  meeting  attended  and $250 for each
telephonic Board of Directors meeting attended. The Company


                                       5
<PAGE>


pays all out-of-pocket fees of attendance. In addition, although no options were
granted to directors in fiscal 2003, the Company has a policy that  non-employee
directors receive  non-qualified  stock options to purchase 15,000 shares of the
Company's common stock per year.


ITEM 11. SECURITY  OWNERSHIP OF CERTAIN  BENEFICIAL  OWNERS AND  MANAGEMENT  AND
         RELATED STOCKHOLDER MATTERS

BENEFICIAL OWNERSHIP OF COMMON STOCK

         The  following  table  sets  forth  as  of  April  20,  2004,   certain
information regarding the ownership of our common stock by (i) each person known
by us to be the beneficial  owner of more than 5% of the  outstanding  shares of
common stock, (ii) each of our directors,  (iii) each of our executive officers,
and  (iv)  all of our  executive  officers  and  directors  as a  group.  Unless
otherwise indicated, the address of each person shown is c/o Xtrana, 590 Burbank
Street, Suite 205, Broomfield, Colorado 80020. References to options to purchase
common stock are either currently  exercisable or will be exercisable  within 60
days of April 20, 2004.

                                        NUMBER OF SHARES       PERCENT OF CLASS
                                       BENEFICIALLY OWNED     BENEFICIALLY OWNED
                                              (1)                     (2)
                                       ------------------     ------------------

DIRECTORS:
John C. Gerdes, Ph.D................       1,430,068                 8.6%
Michael D. Bick, Ph.D...............       1,091,699  (3)            6.6%
N. Price Paschall...................         460,000  (4)            2.7%
Douglas Ayer........................         332,884  (5)            2.0%
James H. Chamberlain................         174,000  (6)            1.0%
James Mahoney, Ph.D.................         110,000  (5)              *

5% HOLDERS:
Jack Wheeler........................       1,147,025                 6.9%
Diane Kozwich.......................       1,130,495                 6.8%

All directors and executive
   officers as a group (six persons)       3,598,651  (7)           20.4%

----------
*        Less than 1%.

(1)      Under Rule 13d-3, certain shares may be deemed to be beneficially owned
         by more than one person (if,  for example,  persons  share the power to
         vote or the power to dispose of the shares).  In  addition,  shares are
         deemed to be beneficially owned by a person if the person has the right
         to acquire the shares (for example,  upon exercise of an option) within
         60 days  of the  date as of  which  the  information  is  provided.  In
         computing the percentage  ownership of any person, the amount of shares
         outstanding  is deemed to  include  the  amount of shares  beneficially
         owned  by such  person  (and  only  such  person)  by  reason  of these
         acquisition  rights. As a result,  the percentage of outstanding shares
         of any person as shown in this table does not  necessarily  reflect the
         person's actual ownership or voting power with respect to the number of
         shares of common stock actually outstanding at April 20, 2004.
(2)      Percentage  ownership  is based on  16,533,269  shares of common  stock
         outstanding as of April 20, 2004.


                                       6
<PAGE>


(3)      Includes  68,749  shares of common  stock  subject to options  that are
         currently exercisable or that will become exercisable within 60 days of
         April 20, 2004, and 1,022,950 shares held in the Bick Family Trust.
(4)      Includes   275,000   shares  of  common  stock   subject  to  currently
         exercisable  warrants  and 185,000  shares of common  stock  subject to
         options that are currently  exercisable or that will become exercisable
         within 60 days of April 20, 2004.
(5)      Consists  of  shares  of  common  stock  subject  to  options  that are
         currently exercisable or that will become exercisable within 60 days of
         April 20, 2004.
(6)      Includes  170,000  shares of common  stock  subject to options that are
         currently exercisable or that will become exercisable within 60 days of
         April 20, 2004.
(7)      Includes  866,633  shares of common  stock  subject to options that are
         currently exercisable or that will become exercisable within 60 days of
         April 20, 2004, and 275,000 shares of common stock subject to currently
         exercisable warrants.

         The information as to shares  beneficially  owned has been individually
furnished by the  respective  directors,  named  executive  officers,  and other
stockholders  of the company,  or taken from documents filed with the Securities
and Exchange Commission.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLAN.

         The following table sets forth certain information regarding our equity
compensation plans as of December 31, 2003.

<TABLE>
<CAPTION>
                           NUMBER OF SECURITIES TO    WEIGHTED-AVERAGE EXERCISE       NUMBER OF SECURITIES
                           BE ISSUED UPON EXERCISE       PRICE OF OUTSTANDING        REMAINING AVAILABLE FOR
                           OF OUTSTANDING OPTIONS,      OPTIONS, WARRANTS AND     FUTURE ISSUANCE UNDER EQUITY
                             WARRANTS AND RIGHTS                RIGHTS                 COMPENSATION PLANS
-----------------------    -----------------------    -------------------------   ----------------------------
<S>                               <C>                           <C>                         <C>
Equity compensation
plans approved by
security holders.......           1,689,047                     $0.82                       2,257,587

Equity compensation
plans not approved by
security holders.......             684,755                     $0.91                           --

Total..................           2,373,802                     $0.85                       2,257,587
</TABLE>


         As of December 31,  2003,  we had 684,755  warrants to purchase  common
stock  outstanding,  which are shown in the table  above as equity  compensation
plans not  approved by security  holders.  These  warrants are  exercisable  for
prices  ranging from $0.01 to $1.875 with a weighted  average  exercise price of
$0.9105 per share.  The weighted  average  remaining  contractual  life of these
warrants at December 31, 2003,  was 3.9 years.  These  warrants have  expiration
dates ranging from 2004 to 2011.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

         There are no proposed  transactions or series of related  transactions,
nor were there any transactions or series of related  transactions during fiscal
2002 and 2003,  to which the Company was a party,  in which the amount  involved
exceeded or will exceed  $60,000 and in which any director,  executive  officer,
holder of more than 5% of our common stock or any member of the immediate family
of any of the foregoing  persons had or will have a direct or indirect  material
interest.

ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K

         (a)      Listing of Exhibits
                  EXHIBIT NO.

                  2.1      Assignment  Agreement  dated January 24, 2004 between
                           the  Company  and  Applera  Corporation,  though  its
                           Applied Biosystems Group. *
                  3.1      Certificate of Incorporation. (1)
                  3.2      Bylaws. (1)
                  4.1      Shareholder Rights Plan. (3)


                                       7
<PAGE>


                  10.1     Executive  Employment  Agreement  of Michael D. Bick,
                           Ph.D. (4)
                  10.2     1993 Stock Incentive Plan. (2)
                  10.3     2000 Stock Incentive Plan. (5)
                  10.4     Lease Agreement - Broomfield, Colorado. (6)
                  10.4.1   Lease Addendum Two for Modification of Rent and Early
                           Termination  of Lease dated November 11, 2003 between
                           the Company and James M. Roswell  d/b/a  Burbank East
                           Business Park. *
                  10.4.2   Lease  Addendum  Three for  Modification  of Rent and
                           Early  Termination  of Lease dated  February 12, 2004
                           between  the  Company  and  James  M.  Roswell  d/b/a
                           Burbank East Business Park. *
                  14.1     Code of Ethical Conduct.
                  23.1     Consent of Independent Auditors. *
                  24.1     Power of Attorney. *
                  31.1     Certificate of our Chief Executive  Officer and Chief
                           Financial Officer pursuant to Rule 13a-14(a).
                  32.1     Certificate of our Chief Executive  Officer and Chief
                           Financial Officer pursuant to Rule 13a-14(b).

                  * Previously filed on Form 10-KSB.

                  (1)      Incorporated   by  reference   to  the   Registrant's
                           Registration   Statement   on  Form  S-1   (File  No.
                           33-20584).
                  (2)      Incorporated by reference to the Registrant's  Annual
                           Report  on  Form  10-K  for  the  fiscal  year  ended
                           December 31, 1994.
                  (3)      Incorporated  by reference to  Registrant's  Form 8-A
                           filed June 26, 1998.
                  (4)      Incorporated by reference to the Registrant's  Annual
                           Report  on Form  10-KSB  for the  fiscal  year  ended
                           December 31, 1999.
                  (5)      Incorporated by reference to Registrant's  Definitive
                           Proxy Statement filed on June 23, 2000.
                  (6)      Incorporated  by reference to  Registrant's  Form 8-K
                           filed January 25, 2001.

         (b)      Reports on Form 8-K filed  during the fourth  quarter of 2003:
                  None


                                       8
<PAGE>


                                   SIGNATURES


         In  accordance  with  Section  13 or 15(d)  of the  Exchange  Act,  the
registrant  caused  this  report to be signed on its behalf by the  undersigned,
thereunto duly authorized.

                                    Xtrana, Inc.


Date:    April 28, 2004             BY:  /S/ JAMES H. CHAMBERLAIN
                                        ----------------------------------------
                                        James H. Chamberlain
                                        Chief Executive Officer and Chief
                                        Financial Officer

         In accordance with Section 13 or 15(d) of the Exchange Act, this report
has been signed below by the following  persons on behalf of the  registrant and
in the capacities and on the dates indicated.


/S/ MICHAEL D. BICK              Chairman of the Board            April 28, 2004
-------------------------          of Directors
Michael D. Bick, Ph.D.


/S/ JAMES H. CHAMBERLAIN         Chief Executive Officer,         April 28, 2004
-------------------------          Chief Financial Officer
James H. Chamberlain                and Director


         *                       Director                         April 28, 2004
-------------------------
Douglas L. Ayer


         *                       Director                         April 28, 2004
-------------------------
N. Price Paschall


         *                       Director                         April 28, 2004
-------------------------
John C. Gerdes, Ph.D.


         *                       Director                         April 28, 2004
-------------------------
James Mahony, Ph.D.


         * By:   /S/ JAMES H. CHAMBERLAIN
                 -----------------------------
                  James H. Chamberlain
                  As Attorney-In-Fact


                                       9